238 related articles for article (PubMed ID: 25943856)
1. Standardized classification unsuitable for spontaneous reporting: the example of osteonecrosis of the jaw.
de Boissieu P; Trenque T
Expert Opin Drug Saf; 2015 Jul; 14(7):1015-21. PubMed ID: 25943856
[TBL] [Abstract][Full Text] [Related]
2. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database.
de Boissieu P; Gaboriau L; Morel A; Trenque T
Fundam Clin Pharmacol; 2016 Oct; 30(5):450-8. PubMed ID: 27315575
[TBL] [Abstract][Full Text] [Related]
4. The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan.
Yuh DY; Chang TH; Huang RY; Chien WC; Lin FG; Fu E
J Dent; 2014 Oct; 42(10):1343-52. PubMed ID: 24907558
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.
Nicolatou-Galitis O; Kouri M; Papadopoulou E; Vardas E; Galiti D; Epstein JB; Elad S; Campisi G; Tsoukalas N; Bektas-Kayhan K; Tan W; Body JJ; Migliorati C; Lalla RV;
Support Care Cancer; 2019 Feb; 27(2):383-394. PubMed ID: 30353228
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Amigues C; Fresse A; Roux CH; Gauthier S; Vieillard MH; Drici MD; Breuil V;
Joint Bone Spine; 2023 Dec; 90(6):105599. PubMed ID: 37271278
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.
Ulmner M; Jarnbring F; Törring O
J Oral Maxillofac Surg; 2014 Jan; 72(1):76-82. PubMed ID: 23992777
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature.
Kanwar N; Bakr MM; Meer M; Siddiqi A
Br Dent J; 2020 Jun; 228(11):886-892. PubMed ID: 32541753
[TBL] [Abstract][Full Text] [Related]
9. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
10. Osteonecrosis of the jaw and nonmalignant disease: is there an association with rheumatoid arthritis?
Lescaille G; Coudert AE; Baaroun V; Javelot MJ; Cohen-Solal M; Berdal A; Goudot P; Azérad J; Ruhin B; Descroix V
J Rheumatol; 2013 Jun; 40(6):781-6. PubMed ID: 23504384
[TBL] [Abstract][Full Text] [Related]
11. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
12. Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database.
Bejhed RS; Kharazmi M; Hallberg P
Ann Pharmacother; 2016 Aug; 50(8):616-24. PubMed ID: 27179251
[TBL] [Abstract][Full Text] [Related]
13. [Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management].
Dupic G; Collangettes D; Dillies AF; Calvet L; Tournilhac O; Bay JO; Mahammedi H
Bull Cancer; 2015 Dec; 102(12):1010-9. PubMed ID: 26607453
[TBL] [Abstract][Full Text] [Related]
14. [Bisphosphonate-related osteonecrosis of the jaw-after a decade has passed].
Yoneda T
Clin Calcium; 2014 Mar; 24(3):407-15. PubMed ID: 24576938
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-related osteonecrosis of the jaw: an Italian post-marketing surveillance analysis.
Parretta E; Sottosanti L; Sportiello L; Rafaniello C; Potenza S; D'Amato S; González-González R; Rossi F; Colella G; Capuano A
Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S31-40. PubMed ID: 25171157
[TBL] [Abstract][Full Text] [Related]
16. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.
Fusco V; Santini D; Armento G; Tonini G; Campisi G
Expert Opin Drug Saf; 2016 Jul; 15(7):925-35. PubMed ID: 27074901
[TBL] [Abstract][Full Text] [Related]
17. Dental extraction as a risk factor for bisphosphonate related osteonecrosis of the jaw in cancer patients: an update.
Utreja A; Almas K; Javed F
Odontostomatol Trop; 2013 Jun; 36(142):38-46. PubMed ID: 24073539
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity.
Koth VS; Figueiredo MA; Salum FG; Cherubini K
Dentomaxillofac Radiol; 2016; 45(7):20160049. PubMed ID: 27167455
[TBL] [Abstract][Full Text] [Related]
19. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
Assaf AT; Smeets R; Riecke B; Weise E; Gröbe A; Blessmann M; Steiner T; Wikner J; Friedrich RE; Heiland M; Hoelzle F; Gerhards F
Anticancer Res; 2013 Sep; 33(9):3917-24. PubMed ID: 24023329
[TBL] [Abstract][Full Text] [Related]
20. A case of early detection of bisphosphonate-related osteonecrosis of the jaw.
Mori M; Koide T; Matsui Y; Matsuda T
Indian J Pharmacol; 2015; 47(3):334-5. PubMed ID: 26069377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
